Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/CACNA1D_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CACNA1D_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CACNA1D_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CACNA1D_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001095913 | Breast | IDC | regulation of metal ion transport | 52/1434 | 406/18723 | 1.76e-04 | 2.97e-03 | 52 |
GO:008606511 | Breast | IDC | cell communication involved in cardiac conduction | 13/1434 | 58/18723 | 3.59e-04 | 5.18e-03 | 13 |
GO:00432703 | Breast | IDC | positive regulation of ion transport | 36/1434 | 275/18723 | 1.11e-03 | 1.22e-02 | 36 |
GO:002289812 | Breast | IDC | regulation of transmembrane transporter activity | 36/1434 | 278/18723 | 1.35e-03 | 1.40e-02 | 36 |
GO:00613373 | Breast | IDC | cardiac conduction | 16/1434 | 98/18723 | 3.06e-03 | 2.60e-02 | 16 |
GO:0051924 | Breast | IDC | regulation of calcium ion transport | 32/1434 | 255/18723 | 3.94e-03 | 3.22e-02 | 32 |
GO:00423912 | Breast | IDC | regulation of membrane potential | 49/1434 | 434/18723 | 4.04e-03 | 3.25e-02 | 49 |
GO:00324125 | Breast | IDC | regulation of ion transmembrane transporter activity | 33/1434 | 267/18723 | 4.38e-03 | 3.40e-02 | 33 |
GO:00324096 | Breast | IDC | regulation of transporter activity | 37/1434 | 310/18723 | 4.77e-03 | 3.66e-02 | 37 |
GO:00860015 | Breast | IDC | cardiac muscle cell action potential | 13/1434 | 76/18723 | 4.81e-03 | 3.67e-02 | 13 |
GO:00020271 | Breast | IDC | regulation of heart rate | 16/1434 | 103/18723 | 5.06e-03 | 3.79e-02 | 16 |
GO:0051928 | Breast | IDC | positive regulation of calcium ion transport | 18/1434 | 122/18723 | 5.35e-03 | 3.95e-02 | 18 |
GO:00030125 | Breast | IDC | muscle system process | 50/1434 | 452/18723 | 5.52e-03 | 4.05e-02 | 50 |
GO:00015082 | Breast | IDC | action potential | 19/1434 | 134/18723 | 6.62e-03 | 4.62e-02 | 19 |
GO:0030048 | Colorectum | AD | actin filament-based movement | 44/3918 | 127/18723 | 2.31e-04 | 2.99e-03 | 44 |
GO:00300482 | Colorectum | MSS | actin filament-based movement | 44/3467 | 127/18723 | 1.11e-05 | 2.64e-04 | 44 |
GO:0086001 | Colorectum | MSS | cardiac muscle cell action potential | 26/3467 | 76/18723 | 8.18e-04 | 8.59e-03 | 26 |
GO:0086065 | Colorectum | MSS | cell communication involved in cardiac conduction | 21/3467 | 58/18723 | 1.11e-03 | 1.09e-02 | 21 |
GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
GO:0086091 | Colorectum | MSS | regulation of heart rate by cardiac conduction | 15/3467 | 39/18723 | 2.80e-03 | 2.19e-02 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CACNA1D | SNV | Missense_Mutation | | c.2786N>A | p.Ile929Asn | p.I929N | Q01668 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
CACNA1D | SNV | Missense_Mutation | | c.1960N>G | p.Thr654Ala | p.T654A | Q01668 | protein_coding | tolerated(0.85) | benign(0) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
CACNA1D | SNV | Missense_Mutation | rs748437057 | c.3808N>A | p.Val1270Ile | p.V1270I | Q01668 | protein_coding | tolerated(0.23) | benign(0.047) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
CACNA1D | SNV | Missense_Mutation | rs763383320 | c.158N>T | p.Trp53Leu | p.W53L | Q01668 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CACNA1D | SNV | Missense_Mutation | | c.4330N>A | p.Glu1444Lys | p.E1444K | Q01668 | protein_coding | tolerated(0.15) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CACNA1D | SNV | Missense_Mutation | rs537189630 | c.2458G>A | p.Asp820Asn | p.D820N | Q01668 | protein_coding | tolerated(0.18) | benign(0.001) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CACNA1D | SNV | Missense_Mutation | novel | c.248N>T | p.Arg83Ile | p.R83I | Q01668 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CACNA1D | SNV | Missense_Mutation | novel | c.1765N>A | p.Glu589Lys | p.E589K | Q01668 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CACNA1D | SNV | Missense_Mutation | | c.4642T>A | p.Cys1548Ser | p.C1548S | Q01668 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AQ-A0Y5-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | SD |
CACNA1D | SNV | Missense_Mutation | rs779080006 | c.6121C>T | p.Arg2041Cys | p.R2041C | Q01668 | protein_coding | tolerated_low_confidence(0.15) | probably_damaging(0.931) | TCGA-BH-A0H6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | blocker | 135651305 | VERAPAMIL | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | activator | 135650283 | | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | FELODIPINE | FELODIPINE | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 178103560 | AMLODIPINE | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | blocker | CHEMBL1280 | VERAPAMIL HYDROCHLORIDE | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | celecoxib | CELECOXIB | 22336956 |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | blocker | CHEMBL1201729 | DRONEDARONE HYDROCHLORIDE | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | modulator | CHEMBL940 | GABAPENTIN | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | blocker | CHEMBL1480 | FELODIPINE | |
776 | CACNA1D | ION CHANNEL, CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | 135650723 | NITRENDIPINE | |